SUMOylation regulates nuclear accumulation and signaling activity of the soluble intracellular domain of the ErbB4 receptor tyrosine kinase

Autor: Knittle, Anna M., Helkkula, Maria, Johnson, Mark S., Sundvall, Maria, Elenius, Klaus

Publikováno v: In Journal of Biological Chemistry 1 December 2017 292(48):19890-19904

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Time-resolved dissection of early phosphoproteome and ensuing proteome changes in response to TGF-β.

Autor: D'Souza, Rochelle C. J., Knittle, Anna M., Nagaraj, Nagarjuna, van Dinther, Maarten, Choudhary, Chunaram, ten Dijke, Peter, Mann, Matthias, Sharma, Kirti

Publikováno v: Science Signaling; 7/22/2014, Vol. 7 Issue 335, p1-16, 16p

An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations.

Autor: Chakroborty D; Institute of Biomedicine, University of Turku, Turku, Finland.; Medicity Research Laboratories, University of Turku, Turku, Finland.; Turku Doctoral Programme of Molecular Medicine, Turku, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland., Ojala VK; Institute of Biomedicine, University of Turku, Turku, Finland.; Medicity Research Laboratories, University of Turku, Turku, Finland.; Turku Doctoral Programme of Molecular Medicine, Turku, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland., Knittle AM; Institute of Biomedicine, University of Turku, Turku, Finland., Drexler J; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Tamirat MZ; Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland.; InFLAMES Research Flagship Center, Åbo Akademi University, Turku, Finland.; Graduate School of Åbo Akademi University (Informational and Structural Biology Doctoral Network), Turku, Finland., Ruzicka R; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Bosch K; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Woertl J; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Schmittner S; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Elo LL; Institute of Biomedicine, University of Turku, Turku, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland., Johnson MS; Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland.; InFLAMES Research Flagship Center, Åbo Akademi University, Turku, Finland., Kurppa KJ; Institute of Biomedicine, University of Turku, Turku, Finland.; Medicity Research Laboratories, University of Turku, Turku, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland., Solca F; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Elenius K; Institute of Biomedicine, University of Turku, Turku, Finland.; Medicity Research Laboratories, University of Turku, Turku, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.; Department of Oncology, Turku University Hospital, Turku, Finland.

Publikováno v: Cancer research communications [Cancer Res Commun] 2022 Jan 07; Vol. 2 (1), pp. 10-27. Date of Electronic Publication: 2022 Jan 07 (Print Publication: 2022).